- July 23, 2014
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Invests US$ 30 Million in Remiges BioPharma Fund, LP to Foster Early Biotech Start-ups
Taiho Pharmaceutical Co., Ltd.(HQ: Tokyo, President and Representative Director: Masayuki Kobayashi, hereinafter "Taiho"), a fully-fledged oncology pharmaceutical company, announced today that the company will be investing US$ 30 million in Remiges BioPharma Fund (hereinafter "Remiges Fund"), a newly formed biotech venture capital fund.
Taiho has a long history of developing new therapeutic options to serve the needs of oncologists and cancer patients. Our development of TAS-102 is an example of our commitment to patients diagnosed with metastatic colorectal cancer whose disease progressed after or who were intolerant to standard therapies. At the same time, we recognize the importance of collaborating with academia and biotech ventures outside Japan for efficient and effective biopharmaceutical innovation.
Taiho hopes to use the investment in Remiges Fund as the platform for open innovation – an outreach for innovative technologies. Through Remiges' well-connected US-Japan cross border investment team, Taiho will be tapping into the US/Europe biotech start-up community and catalyze the company's R&D to deliver innovative cancer treatment to patients.
Information in this news release was current as of the original release date.